## **Core Concept**
The question tests knowledge of the management of hemophilia, specifically the pharmacological agents used to increase factor VIII activity. Hemophilia A is a genetic disorder caused by missing or defective factor VIII, a clotting protein. The goal of treatment is to replace or augment the deficient factor.

## **Why the Correct Answer is Right**
Desmopressin (DDAVP) is a synthetic analogue of vasopressin that works by releasing factor VIII and von Willebrand factor from storage sites into the bloodstream, thereby temporarily increasing their levels. This makes option **B. Desmopressin** the correct answer. Desmopressin is particularly useful for patients with mild hemophilia A and is often used as a first-line treatment for acute episodes or prophylactically before surgery.

## **Why Each Wrong Option is Incorrect**
- **Option A:** Tranexamic acid is an antifibrinolytic agent used to prevent excessive bleeding but does not increase factor VIII activity directly.
- **Option C:** Tranexamic acid and ε-aminocaproic acid are both antifibrinolytics; they do not increase factor VIII levels but work by inhibiting fibrinolysis.
- **Option D:** Fresh frozen plasma (FFP) contains all clotting factors, including factor VIII, but its use is not specific for increasing factor VIII activity and carries a risk of volume overload and transfusion reactions.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that desmopressin is effective only in patients with mild hemophilia A who have some residual factor VIII activity. It is not effective in severe hemophilia A where patients have very low or undetectable levels of factor VIII.

## **Correct Answer:** B. Desmopressin